Acute antipsychotic-induced akathisia revisited

The British Journal of Psychiatry : the Journal of Mental Science
Michael Poyurovsky

Abstract

Akathisia remains one of the most prevalent and distressful antipsychotic-induced adverse events. Effective and well-tolerated treatment is a major unmet need in akathisia that merits a search for new remedies. Accumulating evidence indicates that agents with marked serotonin-2A receptor antagonism may represent a new class of potential anti-akathisia treatment.

References

Apr 22, 1999·The British Journal of Psychiatry : the Journal of Mental Science·A P Boardman
Jul 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M Poyurovsky, A Weizman
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
May 16, 2007·Journal of Clinical Psychopharmacology·Bora BaskakAli Kemal Gogus
Mar 5, 2008·The American Journal of Psychiatry·Michael PoyurovskyAbraham Weizman
Mar 18, 2008·Journal of Clinical Psychopharmacology·Keming GaoJoseph R Calabrese
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Del D MillerUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 2, 2008·Expert Opinion on Pharmacotherapy·Atheir Abbas, Bryan L Roth
Apr 4, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ayelet AvitalRoni Shiloh
Apr 25, 2009·The Journal of Clinical Psychiatry·John M KaneSheila Assunção-Talbott

❮ Previous
Next ❯

Citations

Jul 28, 2012·Psychiatry and Clinical Neurosciences·Yasuhiko HashimotoMasami Tensho
Jul 13, 2011·Journal of Psychopharmacology·Karen D ErscheTrevor W Robbins
Jun 4, 2010·Neuropsychiatric Disease and Treatment·Lars K HansenDavid S Baldwin
Nov 30, 2014·Neurologic Clinics·Shyamal H MehtaKapil D Sethi
May 3, 2012·Parkinsonism & Related Disorders·Roser Ribosa-NoguéJaime Kulisevsky
Dec 22, 2010·Neurologic Clinics·Stanley N CaroffE Cabrina Campbell
Dec 20, 2015·CNS Spectrums·James B LohrMounir A Soliman
Nov 30, 2013·The International Journal of Neuropsychopharmacology·Zacharias G Laoutidis, Christian Luckhaus
Sep 6, 2014·Journal of Palliative Medicine·Elizabeth DurkinColeen Kayden
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·T Scott Stroup, Neil Gray
Apr 29, 2020·Pharmacotherapy·Constance L ChowAmy M VandenBerg
Mar 29, 2014·International Clinical Psychopharmacology·Michael PoyurovskyAbraham Weizman
Apr 25, 2018·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Tamara PringsheimThomas R E Barnes
Oct 22, 2015·Journal of Clinical Psychopharmacology·Michael Poyurovsky, Abraham Weizman
Feb 20, 2021·The South African Journal of Psychiatry : SAJP : the Journal of the Society of Psychiatrists of South Africa·Francois-Pierre JoubertLaila Asmal
Mar 9, 2021·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Marcos Gómez-RevueltaBenedicto Crespo-Facorro
Jul 3, 2021·Journal of the Academy of Consultation-Liaison Psychiatry·Tyler G BoyceMadeleine A Becker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The British Journal of Psychiatry : the Journal of Mental Science
Del D MillerClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
The Journal of Neuropsychiatry and Clinical Neurosciences
Brendan T CarrollCamilo Muñoz
Biochimica Et Biophysica Acta
Jose Miguel Bras, Andrew Singleton
Archives of General Psychiatry
A J Gelenberg, M R Mandel
© 2021 Meta ULC. All rights reserved